Real World Evidence, Center of Excellence, Boehringer Ingelheim USA, Ridgefield, CT, USA.
Nippon Boehringer Ingelheim, Tokyo, Japan.
ESC Heart Fail. 2023 Jun;10(3):1996-2009. doi: 10.1002/ehf2.14321. Epub 2023 Apr 5.
Contemporary estimates of heart failure (HF) prevalence in Japan are scarce. We aimed to estimate HF prevalence and trends in Japan using nationally representative, large administrative claims databases.
This retrospective analysis used data from the Japan Medical Data Center (JMDC) (age ≤74 years) and the Medical Data Vision (MDV) (all ages) databases (study period: 1 January 2014-31 December 31 2019). We calculated HF prevalence using crude and sex-/age-standardized models (weighting based on Japanese census data, 2014-2019). Among 8 954 313 individuals aged ≤74 years from JMDC, and 27 920 174 of all ages from MDV, the cumulative 6 year (2014-2019) crude and sex-/age-standardized prevalence of HF per 1000 persons (95% confidence intervals) in Japan was 21.80 [21.70, 21.89] and 41.79 [30.25, 56.11] using JMDC and 65.09 [65.00, 65.18] and 60.95 [46.94, 77.62], respectively, using MDV. We observed an increasing yearly trend in crude HF prevalence per 1000 persons: 11.12 in 2014 and 14.69 in 2019 for JMDC; 58.09 and 77.18, respectively, for MDV. There was an overall increasing trend of comorbidities over time (2014-2019) among HF patients, especially in type 2 diabetes, malignant cancer, chronic kidney disease, and atrial fibrillation. From 2014 to 2019, the percentage of patients in JMDC with type 2 diabetes increased from 15.4% to 20.8% and 23.4% to 31.5% in MDV; malignant cancer frequency increased from 16.5% to 20.1% in JMDC and 18.8% to 23.9% in MDV; frequency of chronic kidney disease increased from 14.8% to 17.7% in JMDC and 18.2% to 22.7% in MDV; and frequency of atrial fibrillation increased from 13.6% to 15.6% in JMDC and 23.8% to 29.0% in MDV.
We estimated that the prevalence of HF in Japan was 2.2-3.7% for patients aged ≤74 during the period 2014-2019 using the JMDC database, while the prevalence for patients of all ages was 6.5% using the MDV database.
目前日本心力衰竭（HF）的患病率数据有限。本研究旨在使用全国代表性的大型行政索赔数据库来评估日本 HF 的患病率和趋势。
本回顾性分析使用了来自日本医疗数据中心（JMDC）（年龄≤74 岁）和医疗数据视野（MDV）（所有年龄）数据库的数据（研究期间：2014 年 1 月 1 日至 2019 年 12 月 31 日）。我们使用粗患病率和性别/年龄标准化模型（基于日本人口普查数据进行加权，2014-2019 年）来计算 HF 患病率。在 JMDC 中，年龄≤74 岁的 8954313 人和 MDV 中所有年龄的 27920174 人中，2014-2019 年期间每 1000 人（95%置信区间）的 HF 粗患病率（21.80[21.70，21.89]）和性别/年龄标准化患病率（41.79[30.25，56.11]）分别为 21.80[21.70，21.89]和 41.79[30.25，56.11]。使用 JMDC 观察到 HF 粗患病率每年呈上升趋势：2014 年为 11.12，2019 年为 14.69；MDV 分别为 58.09 和 77.18。HF 患者的合并症随时间呈总体上升趋势（2014-2019 年），尤其是 2 型糖尿病、恶性肿瘤、慢性肾脏病和心房颤动。2014 年至 2019 年，JMDC 中 2 型糖尿病患者比例从 15.4%增加到 20.8%和 23.4%到 31.5%；恶性肿瘤频率从 JMDC 的 16.5%增加到 20.1%和 MDV 的 18.8%到 23.9%；慢性肾脏病频率从 JMDC 的 14.8%增加到 17.7%和 MDV 的 18.2%到 22.7%；心房颤动频率从 JMDC 的 13.6%增加到 15.6%和 MDV 的 23.8%到 29.0%。
本研究使用 JMDC 数据库估计，2014-2019 年期间年龄≤74 岁的 HF 患病率为 2.2%-3.7%，而 MDV 数据库中所有年龄的 HF 患病率为 6.5%。
